UroGen reports 68.0 million ZUSDURI revenue in Q3 2026, up 35% quarter over quarter
FROM THE WIRE · GLOBENEWSWIRE.COM
ZUSDURI ® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen's NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date set for June 14, 2027 Announced first…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong quarterly ZUSDURI revenue growth is relevant for the stock, alongside the UGN-103 PDUFA date in June 2027.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01ZUSDURI generated 68.0 million dollars in revenue in the third quarter of 2026.
- 02The FDA accepted the NDA for UGN-103, with a PDUFA goal date of June 14, 2027.
- 03The first patient was dosed in the UGN-501 Phase 1 trial.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets